Milnacipran

Drug Profile

Milnacipran

Alternative Names: Dalcipran; F 2207; Impulsor; Ixel; JONCIA; Midacipran; Midalcipran; Milnacipran Pierre Fabre Medicament; Savella; TN 912; Toledomin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pierre Fabre
  • Developer Allergan; Asahi Kasei; Pierre Fabre; University of Tennessee
  • Class Amides; Amines; Analgesics; Antidepressants; Cyclopropanes; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fibromyalgia; Major depressive disorder
  • Discontinued Vulvodynia

Most Recent Events

  • 29 Jun 2017 Discontinued - Phase-III for Vulvodynia in USA (PO)
  • 10 Apr 2015 Milnacipran is still registered for Fibromyalgia in Australia
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top